Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today highlighted results from an independently led, National Institute of Mental Health-funded randomized trial published in Nature Human Behaviour examining SilverCloud® by Amwell®, the company's digital behavioral health solution.

Conducted across 26 U.S. colleges and universities, the study included 6,205 students at clinical or high-risk levels for anxiety, depression, and/or eating disorders, making it one of the largest independent studies of its kind.

The study, led by renowned investigators from Washington University, Penn State University and University of California, Los Angeles, used a proactive care model designed to reach students before conditions worsened. Researchers screened nearly 40,000 students and offered support to those identified as being at elevated risk, rather than relying only on traditional pathways that require students to seek care on their own.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.